semaglutide peak effect Two-year effects of in adults with overweight or obesity: the STEP 5 trial Semaglutide Review: 'The Drug Helped

Metformin monotherapy was allowed during Part A and was required during Part B of the study

The FDAs decision today brings hope to the millions of adults living with both conditions, offering a new treatment option that represents a major advancement for my patients. The label expansion for OZEMPIC could help Novo stay ahead in the increasingly competitive obesity market, which has recently seen a surge in clinical developments

[6] Rossi A, et al

Yet by 2000, a strategy had emerged to prolong the effect of GLP-1 signaling: generate DPP-4 resistant peptides that bind and activate (i.e., agonize) GLP-1R

Its a targeted, scalable solution for weight and metabolic health, built to plug into what your company already provides